Ambicare News
- Ambicare chief planning to drive sales up to £10m
- Don't be so glum, Posh... you CAN beat acne
- Ambicare looks abroad for growth
- Light at the end of the tunnel for acne sufferers
- Dr Hilary Jones discusses "Lustre Pure Light for acne"
- Acne Treatment Breakthrough
- Ambicare sees bright future for acne treatment system
- Ambicare Health appoints Paul J Donnelly as CEO
- Lustre Pure Light media pack
- Ambicare Health NICE statement
Ambicare Health Appoints Dr Neil MacGilp as Non-Executive Director
Ambicare Health, the Scottish developer of ambulatory light sources for medical and consumer healthcare applications, has appointed Dr Neil MacGilp as non-executive director.
The appointment coincides with Ambicare Health's skin cancer sticking plaster treatment, Ambulight PDT, achieving wider distribution, and the imminent launch of its innovative light-based acne treatment.
David Lawrence, Chairman, Ambicare Health, said: "We are pleased to welcome Neil to the Board. Neil's experience and expertise will be extremely valuable for the business, particularly as we move into commercialisation and future product design. Neil also has a great network that the company will benefit from. We expect to add further expertise to the Board as the company develops further."
Dr MacGilp has decades of medical technology experience, including more than 30 years with Proctor & Gamble and SAB throughout Europe and the US. Most recently, founding InnoGenis, a consultancy dedicated to technology and innovation coaching.
He has a proven track record in transforming technology into commercially successful products, and has thorough knowledge of the organisational approached required to achieve this success.
Dr Neil MacGilp said: "Ambicare Health has created products which have the potential to revolutionise patients' experience of skin cancer and acne treatment. Its products are innovative and effective, and I'm excited to become a part of this burgeoning success story. I'm confident that the company will achieve great things in the UK, Europe and worldwide and I am eager to start working with the exceptional team which is already in place at Ambicare."
For further information, contact:
Stephanie Robertson
Weber Shandwick
T: 0131 556 6649
M: 07809 665773
srobertson@webershandwick.com
Jennifer Butler
Weber Shandwick
T: 0131 556 6649
M: 07770 886937
jbutler@webershandwick.com
Notes to editors:
Ambulight Photo Dynamic Therapy (PDT) Technology
The Ambulight PDT is a light source intended for use in topical Photodynamic Therapy (PDT) of non melanoma skin cancers. It emits light with a peak wavelength of 640nm and a full width half maximum (FWHM) of 20nm. The irradiance of light emitted from the Ambulight PDT is 7mW/cm2. It delivers a total light dose of 75 J/cm2 to the treatment site and is designed to be used in conjunction with a pharmaceutical cream. Ambicare's products can be used outside the clinical environment and allow patients to carry out other activities whilst being treated. Ambicare's technology is IP protected with six patents granted and pending.
The alternative treatment methods to PDT are surgery, use of topical creams and cryotherapy. Each of these can be painful, irritate the skin, leave scarring and can be highly stressful for the patient. PDT treatment is less invasive than surgery and avoids the scarring associated with surgical removal of the lesion which can often require an in-patient hospital stay. Ambulight PDT gives healthcare providers the opportunity to shift treatment from hospitals to primary care, such as GP surgeries or office based dermatologists.
Ambicare plans to launch an anti-acne product during 2011. This product will not require to be used in conjunction with a pharmaceutical cream and can be used with existing acne treatment.
14th June 2011
